Department of Medical Laboratory, Shanghai Sixth Hospital, Shanghai Jiaotong University, Shanghai, China.
J Surg Oncol. 2011 Dec;104(7):836-40. doi: 10.1002/jso.21948. Epub 2011 Jun 7.
Previous studies have suggested that the aberrant expression of Stanniocalcin-1 (STC1) occurs in tumor cells. In this study, we explored whether the circulating STC1 mRNA is a promising biomarker in the peripheral blood in patients with non-small cell lung cancer (NSCLC).
The level of circulating STC1 mRNA was determined with a sensitive quantitative real-time reverse transcription PCR assay. and the data were analyzed by the statistical methods of one-way ANOVA, Mann-Whitney-Wilcoxon U-Test, and Receiver operating characteristic (ROC) curve analysis.
The level of circulating STC1 mRNA in patients with NSCLC was significantly higher than in patients with benign pulmonary disease (P < 0.001) or healthy volunteers (P < 0.001). Higher levels of circulating STC1 mRNA were associated with more advanced tumor stages and histological subtypes. Using a cutoff of 0.055, the sensitivity and specificity of STC1 mRNA levels to differentiate between patients with NSCLC and patients with benign pulmonary diseases was 66.7 and 90.9%, and it was 63.7 and 99.8% for patients with NSCLC and healthy volunteers, respectively.
These findings support our hypothesis that circulating STC1 mRNA is a promising biomarker in the peripheral blood.
先前的研究表明，Stanniocalcin-1（STC1）在肿瘤细胞中表达异常。本研究旨在探索循环 STC1 mRNA 是否可作为非小细胞肺癌（NSCLC）患者外周血中有前途的生物标志物。
采用灵敏的实时定量逆转录 PCR 检测法测定循环 STC1 mRNA 的水平，并采用单因素方差分析、Mann-Whitney-Wilcoxon U 检验和受试者工作特征（ROC）曲线分析等统计方法进行数据分析。
与良性肺部疾病患者（P<0.001）或健康志愿者（P<0.001）相比，NSCLC 患者的循环 STC1 mRNA 水平显著升高。更高水平的循环 STC1 mRNA 与更晚期的肿瘤分期和组织学亚型相关。以 0.055 为截断值，STC1 mRNA 水平区分 NSCLC 患者与良性肺部疾病患者的敏感性和特异性分别为 66.7%和 90.9%，区分 NSCLC 患者与健康志愿者的敏感性和特异性分别为 63.7%和 99.8%。
这些发现支持我们的假设，即循环 STC1 mRNA 是外周血中有前途的生物标志物。
